I just read a study on Medscape Pharmacists called "Teriflunomide: Synergy With First-Line MS Therapies?" and it seems so encourage for Mark to think that this may help us MSers, but of course at double the cost.  Anyways at the end of the paper the following excerpt is posted:

The study was supported by Sanofi-Aventis. Dr. Freedman has declared consulting fees from Biogen Idec, Bayer HealthCare, Celgene, Sanofi-Aventis, Novartis, Merck Serono, and Genzyme. Several of the study coauthors are employees of Sanofi-Aventis. Dr. Freedman is also an uncompensated member of the editorial advisory board for Medscape. Dr. Fox has declared personal consulting or speaking fees from Avanir, Biogen Idec, Genentech, and Novartis.

I just hope that poor Mark Freedman is able to pay his mortgage.